Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06743126
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 60
- Registration Number
- NCT06712927
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06708949
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06683755
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT06594991
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Stanford University (Data Collection Only), Stanford, California, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06581406
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸HonorHealth Research Insisute, Scottsdale, Arizona, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 35
- Registration Number
- NCT06566391
- Locations
- 🇮🇹
Istituto Europeo di Oncologia, Milano, Italy
MAQ-001 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- MabQuest SA
- Target Recruit Count
- 30
- Registration Number
- NCT06514651
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Institut Gustave Roussy, Paris, France
🇫🇷Centre Eugene Marquis, Rennes, France
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Positron Emission TomographyBiological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterProcedure: Single Photon Emission Computed TomographyBiological: CemiplimabBiological: Ipilimumab
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT06508463
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Sagittarius Trial
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.